Home » Elan: CHMP Adopts Negative Opinion on Appeal for Natalizumab
Elan: CHMP Adopts Negative Opinion on Appeal for Natalizumab
Elan Corp. said that the Committee for Medicinal Products for Human Use, the scientific committee of the European Medicines Agency, adopted a negative opinion on the marketing authorization for natalizumab as a treatment for Crohn's disease.
MarketWatch
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May